

ADENOIDECTOMY SURGERY SECONDARY CARE CRITERIA BASED ACCESS (CBA) POLICY

Version:	2425.v3
Recommendation by:	NHS Somerset ICB Clinical Commissioning Policy Forum (CCPF)
Date Ratified:	January 2025
Name of Originator/Author:	EBI Service
Approved by Responsible Committee/Individual:	NHS Somerset Management Board
Publication/issue date:	April 2025
Review date:	Earliest of either NICE publication or 3 years from issue
Target audience:	<p>NHS Somerset ICB:</p> <ul style="list-style-type: none"> • NHS Providers • GP Practices • Contracts Team <p>Medical Directors:</p> <ul style="list-style-type: none"> • Somerset NHS Foundation Trust • Royal United Hospitals Bath NHS FT
Application Form	EBI Generic application form if appropriate to apply

**ADENOIDECTOMY SURGERY SECONDARY CARE
CRITERIA BASED ACCESS (CBA) POLICY**

Section	CONTENTS	Page
	Version Control	1
1	General Principles	2
2	Policy Criteria 2.1 Adenoidectomy 2.2 Adeno +Tonsillectomy (Adenotonsillectomy) 2.3 Adenoidectomy + Grommet Insertion 2.4 Adenoidectomy +Tonsillectomy (Adenotonsillectomy) + Grommet Insertion	2 - 4
3	Evidence Based Interventions Application Process	4 - 5
4	Access To Policy	5
5	References	5

VERSION CONTROL

Document Status:	Current policy
Version:	2425.v3

DOCUMENT CHANGE HISTORY

Version	Date	Comments
1516.v1a	March 2016	New policy
1516.v1a	April 2017	Change to Somerset CCG policy template plus "General Principles" wording amendment
1516.v1b	January 2019	3-year review of policy, IFR to EBI
1819.v1c	December 2021	Adenoidectomy standalone surgery updated NICE publication, inclusion of all criteria for + grommet &/or tonsillectomy
2122.v2	July 2022	Amendment from SCCG to NHS Somerset ICB. New PALS email address
2223.v2a	March 2023	Wording change 3.6
2223.v2b	June 2024	Logo change with amendment to website link and clinical exceptionality wording on 3.6
2425.v2c	October 2024	3-year review, no clinical amendments and amendment to wording under general principles and EBI pathway
2425.v2d	January 2025	Change from PA to CBA pathway from 01.04.25

Equality Impact Assessment (EIA)	April 2018
Quality Impact Assessment QIA	March 2018
Sponsoring Director:	Dr Bernie Marden
Document Reference:	2425.v3

1 GENERAL PRINCIPLES (CBA)

- 1.1 Treatment should only be given in line with these general principles.
- 1.2 Clinicians should assess their patients against the criteria within this policy AND ENSURE that compliance to the policy criteria is met by the patient PRIOR TO a referral to treatment or surgery
- 1.3 Treatment should ONLY be undertaken where there is evidence that the treatment requested is effective and the patient has the potential to benefit from the proposed treatment
- 1.4 The ICB may approve funding for an ASSESSMENT ONLY to enable the Clinician to obtain further clinical evidence to help determine compliance to policy criteria by the patient.

In such cases, patients should be made aware that an assessment DOES NOT mean that they will automatically receive the treatment or surgery. The patient should be advised that, to effectively manage patient safety and ensure efficacy of the treatment/ surgery for the patient, they will only receive treatment or surgery if they meet policy criteria
- 1.5 Patients MUST CONSENT to receiving treatment/ surgery prior to treatment being undertaken
- 1.6 This policy does not apply to patients with suspected malignancy who should continue to be referred under the NHS '2 week wait pathway' rules for assessment and testing as appropriate
- 1.7 Patients with an elevated BMI of 30 or more MAY experience more post-surgical complications including post-surgical wound infection and should be encouraged to lose weight further prior to seeking surgery

<https://www.sciencedirect.com/science/article/pii/S1198743X15007193>
(Thelwall, 2015)
- 1.8 Patients who are smokers should be referred to smoking cessation services to reduce the risk of surgery and improve healing
- 1.9 Where patients are unable to meet the specific treatment criteria set out in this policy, funding approval MAY be sought by submission of a Generic EBI application form to the Evidence Based Interventions (EBI) team on grounds of 'clinical exceptionality'

2 POLICY CRITERIA – CRITERIA BASED ACCESS (CBA)

Patients who are not eligible for treatment under this policy, please refer to Item 3 EVIDENCE BASED INTERVENTIONS APPLICATION PROCESS on how to apply for funding with evidence of clinical exceptionality

2.1 **ADENOIDECTOMY STANDALONE SURGERY**

Adjuvant adenoidectomy **for the treatment of glue ear** should only be offered when one or more of the following clinical criteria are met:

- a) Patients are 18 years of age or under
- b) As part of treatment for obstructive sleep apnoea or sleep disordered breathing in children without tonsillectomy where only the adenoids are contributing to obstructive sleep apnoea or sleep disordered breathing in children
- c) Has Glue Ear and persistent and / or frequent nasal obstruction which is contributed to by adenoidal hypertrophy (enlargement)
- d) As part of the treatment of chronic rhinosinusitis
- e) In preparation for speech surgery in conjunction with the cleft surgery team

If there is a history of cleft palate or palpable palate abnormality such as submucous cleft palate or a history of speech problems before the operation; full multidisciplinary assessment should be carried out before adenoidectomy

2.2 **ADENOIDECTOMY +TONSILLECTOMY (ADENOTONSILLECTOMY) SURGERY**

- a) Patients are 18 years of age or under AND
- b) The Adenoidectomy will be carried out in conjunction with a Tonsillectomy to manage Obstructive Sleep Apnoea (OSA) with symptoms of persistent obstructive sleep apnoea which can be diagnosed with a combination of the following clinical features:
 - A positive sleep study
 - A clear history of an obstructed airway at night: witnessed apnoea's, abnormal postures, increased respiratory effort, loud snoring or stertor
 - Evidence of adeno-tonsillar hypertrophy: direct examination, hot potato or adenoidal speech, mouth breathing / nasal obstruction
 - Significant behavioural change due to sleep fragmentation: daytime somnolence or hyperactivity
 - OSA may also cause morning headache/failure to thrive/night sweats/enuresis

2.3 **ADENOIDECTOMY + GROMMET SURGERY INSERTION**

- a) Patients are 18 years of age or under

- b) With bilateral Otitis Media with Effusion (OME) and without a secondary disability (such as Down's Syndrome or Cleft Palate)
- c) Has Glue Ear and is undergoing grommet surgery for treatment of recurrent acute otitis media
- d) The persistence of bilateral OME and hearing loss should be confirmed over a period of 3 months before intervention is considered. The hearing should be re-tested at the end of this time:
 - During the active observation period, advice on educational and behavioural strategies to minimise the effects of hearing loss should be offered
 - Auto inflation (e.g., OTOVENT) has been trialled unless contra - indicated **AND**
- e) At the end of 3 months the child has persistent bilateral OME with a hearing level in the better ear of 25–30 dBHL or worse averaged at 0.5, 1, 2 and 4 kHz (or equivalent dBA where dBHL not available) **OR**
- f) At the end of 3 months the child has persistent bilateral OME with a hearing loss **less than** 25–30 dBHL but there is significant impact of the hearing loss on a child's developmental, social, or educational status, with one of the below:
 - Delay in speech development
 - Poor listening skills
 - Inattention and behavioural problems
 - Educational or behavioural problems attributable to the hearing loss period (hearing should be retested at the end of this time)
- g) Has Glue Ear and is undergoing surgery for re-insertion of grommets due to recurrence of previously surgically treated otitis media with effusion

2.4 **ADENOIDECTOMY +TONSILLECTOMY (ADENOTONSILLECTOMY) +GROMMET INSERTION SURGERY**

Please refer to the criteria detailed under
 2.2 Adenoidectomy +Tonsillectomy (Adenotonsillectomy) AND
 2.3 Adenoidectomy +Grommet Insertion

3 **EVIDENCE BASED INTERVENTIONS APPLICATION PROCESS**

- 3.1 Patients who are not eligible for surgery under this policy may be considered for surgery on an individual basis where the 'CLINICIAN BEST PLACED' believes exceptional circumstances exist that warrant deviation from the rule of this policy

'THE CLINICIAN BEST PLACED' is deemed to be the GP or Consultant undertaking a medical assessment and/or a diagnostic test/s to determine the health condition of the patient

- 3.2 Completion of a **Generic EBI Funding Application Form** must be sent to the EBI team by the 'clinician best placed' on behalf of the patient
- Note.** applications CANNOT be considered from patients personally
- 3.3 Only electronically completed EBI applications emailed to the EBI Team will be accepted
- 3.4 It is expected that clinicians will have ensured that the patient, on behalf of whom they are forwarding the funding application, has given their consent to the application and are made aware of the due process for receiving a decision on the application within the stated timescale
- 3.5 Generic EBI Funding Applications are considered against '**clinical exceptionality**'. To eliminate discrimination for patients, social, environmental, workplace, and non-clinical personal factors CANNOT be taken into consideration.

For further information on 'clinical exceptionality' please refer to the NHS Somerset ICB EBI webpage [Evidence Based Interventions - NHS Somerset ICB](#) and click on the section titled **Generic EBI Pathway**

- 3.6 Where appropriate photographic supporting evidence can be forwarded with the application form

4 ACCESS TO POLICY

- 4.1 If you would like further copies of this policy or need it in another format, such as Braille or another language, please contact the Patient Advice and Liaison Service on Telephone number: 08000 851067
- 4.2 **Or write to us:** NHS Somerset ICB, Freepost RRKL-XKSC-ACSG, Yeovil, Somerset, BA22 8HR or **Email** us: somicb.pals@nhs.net

5 REFERENCES

- The following sources have been considered when drafting this policy:
- 5.1 The NHS Choices website: <https://www.nhs.uk/conditions/adenoids-and-adenoidectomy/>
- 5.2 **NICE guideline NG233** [Overview | Otitis media with effusion in under 12s | Guidance | NICE](#)
- 5.3 Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s NG202
<https://www.nice.org.uk/guidance/ng202>
- 5.4 Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical practice guideline: Otitis media with effusion executive summary (update). *Otolaryngol Head Neck Surg.* 2016;154(2):201-214. <https://doi.org/10.1177/0194599815624407>. doi: 10.1177/0194599815624407.
- 5.5 Schilder AG, Marom T, Bhutta MF, et al. Panel 7: Otitis media: Treatment and complications. *Otolaryngol Head Neck Surg.* 2017;156(4_suppl):S88-S105. doi: 10.1177/0194599816633697 [doi].
- 5.6 Van dA, Schilder A, Herkert E, Boonacker C, Rovers MM. Adenoidectomy for otitis media in children. *Cochrane Database of Systematic Reviews.* 2010(1). <https://doi.org/10.1002/14651858.CD007810.pub2>. doi: 10.1002/14651858.
- 5.7 European Rhinology Society [European Rhinologic Society | Website of the ERS](#)